{'fraction_non_alphanumeric': 0.07584269662921349, 'fraction_numerical': 0.05898876404494382, 'mean_word_length': 3.7723214285714284, 'pattern_counts': {'":': 0, '<': 5, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Levamisole can reduce the high serum tumour necrosis factor‐α level to a normal level in patients with erosive oral lichen planus

In this study, we measured the baseline serum levels of tumour necrosis factor (TNF)‐α in 158 patients with oral lichen planus (OLP) and in 54 normal control subjects. In total, 60 patients with erosive OLP (EOLP) with relatively high TNF‐α levels were treated with levamisole and the serum TNF‐α levels measured after treatment. We found that the mean ± SD serum level of TNF‐α in patients with either type of EOLP (12.0 ± 1.7 pg/mL, P < 0.005), major EOLP (15.5 ± 4.4 pg/mL, P < 0.001), minor EOLP (11.1 ± 1.8 pg/mL, P < 0.01), or nonerosive OLP (6.1 ± 1.7 pg/mL, P < 0.05) was significantly higher than that (3.8 ± 0.2 pg/mL) of normal control subjects. Treatment with levamisole for a period of 0.5–7.5 months significantly reduced the mean serum TNF‐α level from 22.6 ± 3.4 pg/mL to 6.2 ± 0.8 pg/mL (P < 0.001) in 60 patients with EOLP. We conclude that levamisole can reduce high serum TNF‐α levels to normal in patients with EOLP.